Epigenetics in drug development and diagnostics - digital talks
Watch the talks and panel discussion on demand from our final session of 'Epigenetics - From Bench to Clinic'
Summary
Hear leaders in the field present their latest research on epigenetics in drug development and diagnostics. The short web-based meeting is intended to highlight exciting developments in the field and continue the sharing of knowledge within the epigenetics community.
Webinar objectives
Gain a greater understanding of targeting two epigenetic erasers: Dual inhibition of HDAC6 and LSD1
Demonstrate an increased knowledge of cell free circulating nucleosomes
Understand the emerging role that targeting EZH2 has in the treatment of Follicular Lymphoma
- Gain a greater understanding of targeting two epigenetic erasers: Dual inhibition of HDAC6 and LSD1
- Demonstrate an increased knowledge of cell free circulating nucleosomes
- Understand the emerging role that targeting EZH2 has in the treatment of Follicular Lymphoma
Abcam is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. Interested in receiving P.A.C.E credit for this educational session? Request credit here!
Speakers
- A. Ganesan, University of East Anglia
- Targeting two epigenetic erasers: Dual inhibition of HDAC6 and LSD1
- Mark Eccleston, Volition
- Nu.Q-Capture - Isolation and profiling of tumor derived, cell free circulating nucleosomes
- Neil Michaud, Epizyme
- Targeting EZH2 to Treat Follicular Lymphoma: The Tazverik Story
Moderator
- Rab Prinjha, GSK
Contact
Have a question? Please contact the Abcam Events Team.